Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.
CAB demonstrated comparable efficacy, quality-of-life improvements, and safety in female and male participants with moderate-to-severe acne. As the first fixed-dose, triple-combination topical formulation, CAB represents an important new treatment for acne. J Drugs Dermatol. 2024;23(10):873-881. doi:10.36849/JDD.8484.
Authors
- Steven R. Feldman (ORCID: https://orcid.org/0000-0002-0090-6289)
- J.Q. Del Rosso (ORCID: https://orcid.org/0000-0003-4215-7340)
- Christopher G. Bunick (ORCID: https://orcid.org/0000-0002-4011-8308)
- Eric Guenin
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- Julie Harper (ORCID: https://orcid.org/0000-0001-7181-8721)
- Leon Kircik (ORCID: https://orcid.org/0000-0002-0831-2151)
- Hilary E. Baldwin (ORCID: https://orcid.org/0009-0002-3540-3670)
- Neal Bhatia (ORCID: https://orcid.org/0000-0001-7448-7809)
- Edward Ted Lain
Publication Details
- Journal
- PubMed
- Published
- 2024-10-01
- DOI
- https://doi.org/10.36849/jdd.2024.8484
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00